This study aims to evaluate the clinical performance of blood-based Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) in patients with endometrial and cervical cancer. The researchers will investigate whether MRD detection can identify cancer recurrence earlier than current standard imaging or clinical methods (providing a "lead time"). Participants will undergo blood collection at specific time points, including at diagnosis, after surgery, and during regular follow-up visits. The study will also assess the correlation between MRD status and survival outcomes, such as Relapse-Free Survival (RFS) and Overall Survival (OS). The goal is to establish a foundation for personalized treatment strategies based on molecular monitoring.
Histologically confirmed endometrial cancer or cervical cancer.
Scheduled for or completed standard treatment (Surgery, Adjuvant therapy, or CCRT).
Provision of written informed consent for study participation and biospecimen collection
Synchronous other malignancies (cancer requiring treatment within the last 5 years).
Persistent infection or bleeding tendency that makes repeated blood collection unsafe.
Inability to follow-up or communicate (e.g., due to geographic or cognitive reasons).
Any condition that the principal investigator deems inappropriate for the study.